GlassScriptPhysician profile
Nehru Murati
NPI 1376704676
$266.53
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $219 · 2020: $15.50 · 2022: $13.93 · 2024: $18.59.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $18.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $18.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $38.04 | 2019 | |
| Hologic Sales and Service, LLC | $32.52 | 2022-2024 | Aptima |
| Pfizer INC. | $31.90 | 2019 | |
| Amarin Pharma, INC. | $24.75 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.86 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.08 | 2019 | |
| Sanofi-Aventis U.S. LLC | $16.49 | 2019 | |
| Genentech USA, INC. | $16.30 | 2019 | |
| Janssen Pharmaceuticals, INC | $15.50 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.82 | 2019 | |
| Merck Sharp & Dohme LLC | $14.08 | 2019 | |
| Amgen INC. | $12.21 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $10.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nehru Murati listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.